Mt. Sinai Medical Center, Miami

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Mt. Sinai Medical Center, Miami sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 1 currently recruiting 12 completed top decile by trial count

Mt. Sinai Medical Center, Miami: 13 sponsored US clinical trials, 1 recruiting.

Mt. Sinai Medical Center, Miami sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 5 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Unresectable Locally Advanced NSCLC, with 1 trials.

Top-decile sponsor footprint

Mt. Sinai Medical Center, Miami ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3

Trial to Assess Chelation Therapy in Critical Limb Ischemia

NCT03982693
COMPLETED Phase 3

Trial to Assess Chelation Therapy 2

NCT02733185
COMPLETED Early Phase 1

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

NCT03424746
COMPLETED Phase 4

Contrast Nephropathy and Nitrates

NCT01999517
COMPLETED Phase 2

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

NCT01048554
COMPLETED NA

Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying

NCT01844622
COMPLETED Phase 2

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)

NCT00625573
COMPLETED Phase 2

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

NCT00483301
COMPLETED Phase 2

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

NCT00616564
COMPLETED Phase 2

Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

NCT00217282
COMPLETED Phase 2

Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00682383
COMPLETED Phase 3

Trial to Assess Chelation Therapy (TACT)

NCT00044213
COMPLETED Phase 4

Subcutaneous Amifostine Safety Study

NCT00158041

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 3
Phase 4 2

Therapeutic Areas

Unresectable Locally Advanced NSCLC 1
Contrast Induced Nephropathy 1
Critical Limb Ischemia 1
Diabetes 1

What is open in the Mt. Sinai Medical Center, Miami pipeline

1 recruiting of 13 indexed (8% open); 12 completed (92%).

Phase mix: 5 late (III/IV) vs 7 early (I/II) (balanced across stages).

Top condition: Unresectable Locally Advanced NSCLC (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Mt. Sinai Medical Center, Miami: open-pipeline peers nationwide

Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Mt. Sinai Medical Center, Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%2%4%6%8%10% Total trials Recruiting share Mt. Sinai Medical Center, MiamiAdaptimmuneAgennixAkili Interactive LabsAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical CenterFresenius Medical Care North America
Mt. Sinai Medical Center, Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mt. Sinai Medical Center, Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mt. Sinai Medical Center, Miami page

13 registered trials is a research-attention snapshot, not an endorsement of Mt. Sinai Medical Center, Miami or any single study.

  • 1 of Mt. Sinai Medical Center, Miami's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Unresectable Locally Advanced NSCLC is the condition Mt. Sinai Medical Center, Miami studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Unresectable Locally Advanced NSCLC trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mt. Sinai Medical Center, Miami pipeline card: 13 registered trials from official public datasets.Report a data error.